LIVIVO - Search results -

Search results

Result 1 - 10 of total 73

Search options

Article: What's New in Emergencies, Trauma and Shock? Trauma-associated Venous Thromboembolism: A Potentially Preventable Cause of Morbidity and Mortality.

Mahajan, Kunal

Journal of emergencies, trauma, and shock

2020 Volume 13, Issue 2, Page(s) 105–106

Language	English
Publishing date	2020-06-10
Publishing country	India
Document type	Editorial
ZDB-ID	2461111-6
ISSN	0974-519X ; 0974-2700
ISSN (online)	0974-519X
ISSN	0974-2700
DOI	10.4103/JETS.JETS_34_20
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis.

Mahajan, Kunal / Nagendra, Lakshmi / Dhall, Anil / Dutta, Deep

European journal of internal medicine

2024

Abstract: Objective: Scant data is available on the efficacy and safety of adding ezetimibe to high-intensity statin therapy for early and rapid reduction of low-density lipoprotein cholesterol (LDL-C) within 4-12 weeks of an acute-event in acute coronary ... ...

Abstract	Objective: Scant data is available on the efficacy and safety of adding ezetimibe to high-intensity statin therapy for early and rapid reduction of low-density lipoprotein cholesterol (LDL-C) within 4-12 weeks of an acute-event in acute coronary syndrome (ACS). We undertook this meta-analysis to address this knowledge-gap. Methods: Electronic databases were searched for RCTs involving patients with ACS receiving ezetimibe in intervention arm, and placebo/active comparator in control arm. Primary outcome was to evaluate changes in LDL-C levels post-ACS. Secondary outcomes were to evaluate alterations in other lipid parameters and adverse events. Results: From initially screened 4561 articles, data from 11 studies (20,291 patients) were analyzed. Compared to controls, patients receiving ezetimibe had significantly lower LDL-C at 7-days [MD -19.55 mg/dl(95 %CI:-36.46 to -2.63);P = 0.02;I Conclusion: Addition of ezetimibe to high-intensity statin therapy at the time of ACS event is associated with significantly better cholesterol reduction at day-7,1-month, 3- months and 1-year of follow-up, which translates into a significantly lower recurrent cardiovascular events post an index event of ACS. Concise summary of findings: Addition of ezetimibe to high-intensity statin therapy at the time of acute coronary syndrome (ACS) index event is associated with significantly better low density lipoprotein cholesterol and total cholesterol reduction at day-7, 1-month, 3-months and 1-year of follow-up, which translates into a significantly lower recurrent cardiovascular events (death from any cause, major ACS, non-fatal stroke, non-fatal myocardial infarction, and ischemic stroke) post an index event of ACS.
Language	English
Publishing date	2024-02-08
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	1038679-8
ISSN	1879-0828 ; 0953-6205
ISSN (online)	1879-0828
ISSN	0953-6205
DOI	10.1016/j.ejim.2024.02.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2608: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Obstructive sleep apnea and coronary artery disease: An unholy nexus or a holy alliance?

Mahajan, Sanyam K / Mahajan, Kunal / Sharma, Sunil

Lung India : official organ of Indian Chest Society

2023 Volume 39, Issue 5, Page(s) 460–465

Abstract: Coronary artery disease (CAD) is a significant cause of morbidity and mortality globally, and hypertension, dyslipidemia, diabetes mellitus, and smoking are major cardiovascular (CV) risk factors. Obstructive sleep apnea (OSA) and CAD share an exciting ... ...

Abstract	Coronary artery disease (CAD) is a significant cause of morbidity and mortality globally, and hypertension, dyslipidemia, diabetes mellitus, and smoking are major cardiovascular (CV) risk factors. Obstructive sleep apnea (OSA) and CAD share an exciting relationship, and recently, OSA has emerged as a non-traditional CV risk factor. OSA is characterized by episodic sleep state-dependent collapse of the upper airway, resulting in periodic reductions or cessations in ventilation, with consequent hypoxia, hypercapnia, or arousals from sleep. The oxidative stress and vascular inflammation resulting from the nocturnal hypoxia followed by reoxygenation cycles predispose the patients to the development of atherosclerotic cardiovascular disease (CVD). Untreated OSA is associated with long-term health consequences, including CVD, metabolic disorders, cognitive impairment, and depression. Paradoxically, some recent studies have reported that patients with OSA may suffer less severe CAD due to the development of collateral circulation due to repetitive hypoxia experienced due to OSA.
Language	English
Publishing date	2023-01-10
Publishing country	India
Document type	Journal Article
ZDB-ID	2410801-7
ISSN	0974-598X ; 0970-2113
ISSN (online)	0974-598X
ISSN	0970-2113
DOI	10.4103/lungindia.lungindia_597_21
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Impact of early initiation of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome: A systematic review meta-analysis.

Nagendra, Lakshmi / Mahajan, Kunal / Gupta, Gunjan / Dutta, Deep

Indian heart journal

2023 Volume 75, Issue 6, Page(s) 416–422

Abstract: Objective: Scant data is available on the efficacy and safety of proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) for early and rapid reduction of low-density lipoprotein cholesterol (LDL-C) within 4-8 weeks of an acute event in ... ...

Abstract	Objective: Scant data is available on the efficacy and safety of proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) for early and rapid reduction of low-density lipoprotein cholesterol (LDL-C) within 4-8 weeks of an acute event in patients with acute coronary syndrome (ACS). We undertook this meta-analysis to address this knowledge-gap. Methods: Electronic databases were searched for RCTs involving patients with ACS receiving PCSK9i in intervention arm, and placebo/active comparator in control arm. Primary outcome was to evaluate changes in 1-month LDL-C post ACS. Secondary outcomes were to evaluate alterations in other lipid parameters and adverse events. Results: From initially screened 194 articles, data from 3 studies was analyzed. After 4-weeks therapy, patients receiving PCSK9i had lower LDL-C [MD -0.95 mmol/L (95%CI:-1.51 to -0.40); P = 0.0007; I Conclusion: PCSK9i are highly effective in early reduction of LDL-C along with reduction of early hospital readmissions post-ACS.
MeSH term(s)	Humans ; Acute Coronary Syndrome/drug therapy ; Anticholesteremic Agents/therapeutic use ; Cholesterol, HDL ; Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Proprotein Convertase 9 ; Subtilisins
Chemical Substances	Anticholesteremic Agents ; Cholesterol, HDL ; Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Proprotein Convertase 9 (EC 3.4.21.-) ; Subtilisins (EC 3.4.21.-)
Language	English
Publishing date	2023-09-29
Publishing country	India
Document type	Systematic Review ; Meta-Analysis ; Journal Article
ZDB-ID	604366-5
ISSN	2213-3763 ; 0019-4832
ISSN (online)	2213-3763
ISSN	0019-4832
DOI	10.1016/j.ihj.2023.09.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 616: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Efficacy and safety of luseogliflozin in improving glycaemic and non-glycaemic outcomes in type-2 diabetes: A meta-analysis.

Dutta, Deep / Kadian, Jyoti / Mahajan, Kunal / Dhall, Anil / Sharma, Meha

Diabetes & metabolic syndrome

2023 Volume 17, Issue 3, Page(s) 102742

Abstract: Background & aims: No meta-analysis is available analysing the role of luseogliflozin in type-2 diabetes. We undertook this meta-analysis to address this knowledge-gap.: Methods: Electronic databases were searched for RCTs involving diabetes patients ...

Abstract	Background & aims: No meta-analysis is available analysing the role of luseogliflozin in type-2 diabetes. We undertook this meta-analysis to address this knowledge-gap. Methods: Electronic databases were searched for RCTs involving diabetes patients receiving luseogliflozin in intervention arm, and placebo/active comparator in control arm. Primary outcome was to evaluate changes in HbA1c. Secondary outcomes were to evaluate alterations in glucose, blood pressure, weight, lipids, and adverse events. Results: From initially screened 151 articles, data from 10 RCTs involving 1304 patients was analysed. Individuals receiving luseogliflozin 2.5 mg/d had a significantly lower HbA1c [MD -0.76% (95% CI: 1.01 to -0.51); P < 0.01; I Conclusion: Luseogliflozin has good glycaemic and non-glycaemic benefits similar to other SGLT2 inhibitors and is well tolerated.
MeSH term(s)	Humans ; Hypoglycemic Agents/therapeutic use ; Glycated Hemoglobin ; Diabetes Mellitus, Type 2/complications ; Glucose ; Blood Glucose
Chemical Substances	Hypoglycemic Agents ; Glycated Hemoglobin ; 1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol (C596HWF74Z) ; Glucose (IY9XDZ35W2) ; Blood Glucose
Language	English
Publishing date	2023-03-13
Publishing country	Netherlands
Document type	Journal Article
ZDB-ID	2273766-2
ISSN	1878-0334 ; 1871-4021
ISSN (online)	1878-0334
ISSN	1871-4021
DOI	10.1016/j.dsx.2023.102742
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis.

Dutta, Deep / Mohindra, Ritin / Mahajan, Kunal / Sharma, Meha

Diabetes & metabolism journal

2022 Volume 47, Issue 1, Page(s) 72–81

Abstract: Background: No meta-analysis has analysed efficacy and safety of fast-acting aspart insulin (FIAsp) with insulin pump in type 1 diabetes mellitus (T1DM).: Methods: Electronic databases were searched for randomised controlled trials (RCTs) involving ... ...

Abstract	Background: No meta-analysis has analysed efficacy and safety of fast-acting aspart insulin (FIAsp) with insulin pump in type 1 diabetes mellitus (T1DM). Methods: Electronic databases were searched for randomised controlled trials (RCTs) involving T1DM patients on insulin pump receiving FIAsp in intervention arm, and placebo/active comparator insulin in control arm. Primary outcome was to evaluate changes in 1- and 2-hour post-prandial glucose (1hPPG and 2hPPG). Secondary outcomes were to evaluate alterations in percentage time with blood glucose <3.9 mmol/L (hypoglycaemia), time in range (TIR) blood glucose 3.9 to 10 mmol/L, insulin requirements and adverse events. Results: Data from four RCTs involving 640 patients was analysed. FIAsp use in insulin pump was associated with significantly greater lowering of 1hPPG (mean difference [MD], -1.35 mmol/L; 95% confidence interval [CI], -1.72 to -0.98; P<0.01; I2=63%) and 2hPPG (MD, -1.19 mmol/L; 95% CI, -1.38 to -1.00; P<0.01; I2=0%) as compared to controls. TIR was comparable among groups (MD, 1.06%; 95% CI, -3.84 to 5.96; P=0.67; I2=70%). Duration of blood glucose <3.9 mmol/L was lower in FIAsp group, approaching significance (MD, -0.91%; 95% CI, -1.84 to 0.03; P=0.06; I2=0%). Total hypoglycaemic episodes (risk ratio [RR], 1.35; 95% CI, 0.55 to 3.31; P=0.51; I2=0%), severe hypoglycaemia (RR, 2.26; 95% CI, 0.77 to 6.66; P=0.14), infusion site reactions (RR, 1.35; 95% CI, 0.63 to 2.93; P=0.77; I2=0%), and treatment-emergent adverse events (RR, 1.13; 95% CI, 0.80 to 1.60; P=0.50; I2=0%) were comparable. Conclusion: FIAsp use in insulin pump is associated with better post-prandial glycaemic control with no increased hypoglycaemia or glycaemic variability.
MeSH term(s)	Humans ; Blood Glucose ; Diabetes Mellitus, Type 1/drug therapy ; Hypoglycemia/chemically induced ; Hypoglycemic Agents/therapeutic use ; Insulin/therapeutic use ; Insulin Aspart/therapeutic use
Chemical Substances	Blood Glucose ; Hypoglycemic Agents ; Insulin ; Insulin Aspart (D933668QVX)
Language	English
Publishing date	2022-06-24
Publishing country	Korea (South)
Document type	Journal Article
ZDB-ID	2602402-0
ISSN	2233-6087 ; 2233-6087
ISSN (online)	2233-6087
ISSN	2233-6087
DOI	10.4093/dmj.2022.0035
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Hemiazygous continuation of inferior vena cava draining into the coronary sinus via persistent left superior vena cava: a rare anomaly.

Bhutani, Jaikrit / Batra, Aditya / Doomra, Mridul / Mahajan, Kunal

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace

2022 Volume 93, Issue 1

Abstract: We present a case of left sided inferior vena cava with hemiazygous continuation draining into the coronary sinus via the left persistent superior vena cava. This was incidentally found in an individual referred to our centre for evaluation of ... ...

Abstract	We present a case of left sided inferior vena cava with hemiazygous continuation draining into the coronary sinus via the left persistent superior vena cava. This was incidentally found in an individual referred to our centre for evaluation of palpitations. These caval anomalies are rare, and are often associated with no clinical manifestations. However, it is necessary to recognize them during routine workup to avoid diagnostic and procedural pitfalls.
MeSH term(s)	Humans ; Vena Cava, Superior/abnormalities ; Coronary Sinus ; Persistent Left Superior Vena Cava ; Vena Cava, Inferior ; Drainage
Language	English
Publishing date	2022-06-28
Publishing country	Italy
Document type	Case Reports ; Journal Article
ZDB-ID	1160940-0
ISSN	1122-0643 ; 1120-0391
ISSN	1122-0643 ; 1120-0391
DOI	10.4081/monaldi.2022.2275
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 65: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Efficacy and safety of long-acting growth hormone in adult growth hormone deficiency: A systematic review and meta-analysis.

Dutta, Deep / Mahajan, Kunal / Kumar, Manoj / Sharma, Meha

Diabetes & metabolic syndrome

2022 Volume 16, Issue 2, Page(s) 102421

Abstract: Background & aims: No meta-analysis has analysed efficacy and safety of long-acting growth hormone (GH) therapy in adult GH deficiency. We undertook this meta-analysis to address this gap in knowledge METHODS: Electronic databases were searched for RCTs ...

Abstract	Background & aims: No meta-analysis has analysed efficacy and safety of long-acting growth hormone (GH) therapy in adult GH deficiency. We undertook this meta-analysis to address this gap in knowledge METHODS: Electronic databases were searched for RCTs involving adult GH deficiency patients receiving weekly long-acting GH as compared to daily GH/placebo controls. Primary outcome was to evaluate changes in body-composition parameters. Secondary outcomes were to evaluate alterations in glycaemia and adverse-events. Results: Data from 5 studies involving 648 patients were analysed (4 studies having daily GH as active controls; 1 study having placebo as passive controls). Over 24-34 weeks clinical use, patients receiving long-acting GH had comparable change in lean mass [MD-0.28 kg (95%CI: 0.94 - 0.38); P = 0.41; I Conclusion: Long-acting GH has comparable beneficial impact on body composition parameters in adult GH deficiency, is well tolerated without any increased adverse events.
MeSH term(s)	Adult ; Blood Glucose ; Body Composition ; Diabetes Mellitus/drug therapy ; Growth Hormone ; Human Growth Hormone/therapeutic use ; Humans
Chemical Substances	Blood Glucose ; Human Growth Hormone (12629-01-5) ; Growth Hormone (9002-72-6)
Language	English
Publishing date	2022-02-08
Publishing country	Netherlands
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	2273766-2
ISSN	1878-0334 ; 1871-4021
ISSN (online)	1878-0334
ISSN	1871-4021
DOI	10.1016/j.dsx.2022.102421
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: The role of natriuretic peptide estimation in severe COVID-19.

Mahajan, Kunal / Negi, Prakash

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace

2020 Volume 90, Issue 2

Abstract: Since its inception in Wuhan in December 2019, Coronavirus disease 2019 (COVID-19) has shattered the economies and health-care infrastructures worldwide. Even the best of health-care systems (United States, Italy) have been overwhelmed and collapsed ... ...

Abstract	Since its inception in Wuhan in December 2019, Coronavirus disease 2019 (COVID-19) has shattered the economies and health-care infrastructures worldwide. Even the best of health-care systems (United States, Italy) have been overwhelmed and collapsed because of this unprecedented pandemic. India is preparing itself for the onslaught of Coronavirus. After recording its first case on January 30th, 2020, the rise was slow until the last week of March. However, since then, the number of cases has increased exponentially, and as on April 14th, 2020, there have been more than 10,000 cases of coronavirus disease (COVID-19) in India, which has resulted in more than 350 deaths.
MeSH term(s)	Biomarkers/analysis ; COVID-19 ; COVID-19 Testing ; Clinical Laboratory Techniques ; Coronavirus Infections/complications ; Coronavirus Infections/diagnosis ; Coronavirus Infections/pathology ; Coronavirus Infections/therapy ; Humans ; India ; Natriuretic Peptides/analysis ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/pathology ; Pneumonia, Viral/therapy ; Respiratory Distress Syndrome/diagnosis ; Respiratory Distress Syndrome/etiology ; Respiratory Distress Syndrome/therapy
Chemical Substances	Biomarkers ; Natriuretic Peptides
Keywords	covid19
Language	English
Publishing date	2020-04-27
Publishing country	Italy
Document type	Journal Article
ZDB-ID	1160940-0
ISSN	1122-0643 ; 1120-0391
ISSN	1122-0643 ; 1120-0391
DOI	10.4081/monaldi.2020.1316
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 65: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Early de-escalation of DAPT after PCI: implications of the latest randomized trials in the COVID era.

Mahajan, Kunal / Batra, Aditya

Indian heart journal

2020 Volume 72, Issue 3, Page(s) 209–211

MeSH term(s)	Betacoronavirus ; COVID-19 ; Coronary Artery Disease/complications ; Coronary Artery Disease/epidemiology ; Coronary Artery Disease/therapy ; Coronavirus Infections/complications ; Coronavirus Infections/epidemiology ; Drug-Eluting Stents ; Global Health ; Humans ; Morbidity/trends ; Pandemics ; Percutaneous Coronary Intervention/methods ; Platelet Aggregation Inhibitors/therapeutic use ; Pneumonia, Viral/complications ; Pneumonia, Viral/epidemiology ; Randomized Controlled Trials as Topic ; SARS-CoV-2 ; Treatment Outcome
Chemical Substances	Platelet Aggregation Inhibitors
Keywords	covid19
Language	English
Publishing date	2020-05-23
Publishing country	India
Document type	Letter ; Review
ZDB-ID	604366-5
ISSN	2213-3763 ; 0019-4832
ISSN (online)	2213-3763
ISSN	0019-4832
DOI	10.1016/j.ihj.2020.05.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 616: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito